Immuron AI Stock Analysis
Want to see IMRN full AI Analyst Report?
Immuron (IMRN) AI Stock Analysis
Immuron
(NASDAQ:IMRN)
IMRN scores low primarily due to persistent operating losses and ongoing negative free cash flow that suggest continued funding needs, reinforced by a weak technical trend (price below key moving averages with negative MACD). The main stabilizer is a relatively strong balance sheet with no debt, but valuation remains challenged given negative earnings and no dividend support.
Immuron (IMRN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.98M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.06M
- Price to Earnings (P/E)
- -2.9
- Beta (1Y)
- 0.53
- Revenue Growth
- 10.41%
- EPS Growth
- 42.44%
- Country
- US
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Immuron Business Overview & Revenue Model
Company Description
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activit...
Immuron Financial Statement Overview
Summary
Financials are mixed but skew weak: revenue scaled over multiple years and gross margin is solid (~64% in 2026), yet the company remains unprofitable (2026 net loss -$3.75M; operating loss -$4.63M). Cash flow is the key concern with ongoing negative operating cash flow and free cash flow (~-$3.0M in 2026), implying continued funding needs. The main offset is low balance-sheet risk from having no debt and maintaining meaningful equity ($11.0M).
Income Statement
32NegativeBalance Sheet
61PositiveCash Flow
28Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.69M | 7.55M | 7.29M | 4.90M | 1.80M | 765.19K |
| Gross Profit | 4.96M | 4.87M | 4.77M | 3.34M | 1.74M | 523.50K |
| EBITDA | -4.76M | -4.63M | -5.31M | -5.17M | -3.36M | -3.09M |
| Net Income | -3.83M | -3.75M | -5.22M | -6.94M | -3.79M | -2.85M |
Balance Sheet | ||||||
| Total Assets | 12.99M | 12.99M | 10.09M | 15.55M | 21.99M | 24.86M |
| Cash, Cash Equivalents and Short-Term Investments | 9.02M | 9.02M | 5.87M | 11.66M | 18.99M | 22.11M |
| Total Debt | 0 | 0 | 117.13K | 173.50K | 189.09K | 209.79K |
| Total Liabilities | 1.99M | 1.99M | 2.06M | 2.84M | 2.37M | 1.68M |
| Stockholders Equity | 11.01M | 11.01M | 8.03M | 12.71M | 19.62M | 23.18M |
Cash Flow | ||||||
| Free Cash Flow | -3.20M | -3.00M | -6.14M | -5.88M | -2.50M | -3.14M |
| Operating Cash Flow | -3.20M | -3.00M | -6.14M | -5.88M | -2.49M | -3.13M |
| Investing Cash Flow | 3.18M | 2.97M | -2.90M | 327.56K | -2.74M | 11.74K |
| Financing Cash Flow | 6.82M | 6.35M | 199.75K | 829 | -35.02K | -36.26K |
Immuron Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRN, the sentiment is Neutral. The current price of 0.93 is above the 20-day moving average (MA) of 0.92, below the 50-day MA of 1.11, and below the 200-day MA of 1.01, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 45.89 is Neutral, neither overbought nor oversold. The STOCH value of 73.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMRN.
Immuron Risk Analysis
Immuron disclosed 62 risk factors in its most recent earnings report. Immuron reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksImmuron Peers Comparison
Overall Rating
LPCN45Neutral- IMRN44Neutral
CANF38Underperform
BIVI37.6Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| LPCN | 45Neutral | $17.61M | -1.17 | -46.52% | ― | -13.37% | -33.44% |
| IMRN | 44Neutral | $7.52M | -2.87 | -31.88% | ― | 10.41% | 42.44% |
| CANF | 38Underperform | $5.35M | -0.23 | -182.88% | ― | ― | ― |
| BIVI | 38Underperform | $13.62M | -0.43 | -174.88% | ― | ― | 67.39% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IMRN | Immuron | 0.93 | -0.63 | -40.58% | |
| CANF | Can-Fite BioPharma Ltd | 1.55 | -5.87 | -79.12% | |
| LPCN | Lipocine Inc | 1.59 | -1.23 | -43.62% | |
| BIVI | Biovie Inc. | 1.26 | -0.23 | -15.44% | |
| ASBP | Aspire Biopharma Holdings, Inc. | 8.80 | -117.44 | -93.03% |
Immuron Corporate Events
Immuron Engages LifeSci Capital for Strategic Initiatives
Immuron Limited is an Australian biopharmaceutical company developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases. Its portfolio includes Travelan®, an oral passive immunotherapy for travelers’ diarrhea...
Immuron Cuts U.S. ATM Offering Capacity to $2 Million in Updated F-3 Filing
On October 23, 2026, Immuron Limited reported that it had reduced the capacity of its at-the-market equity offering program with H.C. Wainwright & Co. to an aggregate offering price of about $2.0 million of American Depositary Shares. The company fil...
Immuron Calls November AGM to Decide Board Seats, Incentive Plan and Capital-Raising Capacity
Immuron Limited, an Australia-based biotechnology company dual-listed on the ASX and Nasdaq, develops immunotherapy-based treatments for infectious diseases and related conditions. Its global investor base spans Australia and the U.S., making corpora...
Immuron CEO to Present Company’s Gut Health Pipeline at Emerging Growth Conference
On August 13, 2026, Immuron Limited announced that chief executive Steven Lydeamore will deliver a virtual presentation at the Emerging Growth Conference on August 19, 2026, in the U.S. afternoon session. The appearance underscores ongoing efforts to...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026